- Report
- June 2025
- 100 Pages
Global
From €4529EUR$4,900USD£3,775GBP
- Report
- August 2025
- 192 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 190 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 198 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 199 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 195 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 184 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 190 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 180 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 191 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 180 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 183 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- August 2025
- 197 Pages
Global
From €3277EUR$3,545USD£2,731GBP
€3641EUR$3,939USD£3,035GBP
- Report
- September 2025
- 120 Pages
Global
From €5500EUR$5,950USD£4,584GBP
- Report
- October 2023
- 113 Pages
Global
From €5500EUR$5,950USD£4,584GBP
- Report
- September 2023
- 120 Pages
North America
From €5500EUR$5,950USD£4,584GBP
- Report
- May 2024
- 200 Pages
Global
From €3836EUR$4,150USD£3,198GBP
- Report
- January 2024
- 200 Pages
Global
From €3836EUR$4,150USD£3,198GBP
- Report
- February 2025
Global
From €4575EUR$4,950USD£3,814GBP
- Report
- December 2024
- 200 Pages
Global
From €2311EUR$2,500USD£1,926GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more